Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
作者信息
Qi Xiaolong, Liu Yanna, Wang Jitao, Fallowfield Jonathan A, Wang Jianwen, Li Xinyu, Shi Jindong, Pan Hongqiu, Zou Shengqiang, Zhang Hongguang, Chen Zhenhuai, Li Fujian, Luo Yan, Mei Mei, Liu Huiling, Wang Zhengyan, Li Jinlin, Yang Hua, Xiang Huihua, Li Xiaodan, Liu Tao, Zheng Ming-Hua, Liu Chuan, Huang Yifei, Xu Dan, Li Xiaoguo, Kang Ning, He Qing, Gu Ye, Zhang Guo, Shao Chuxiao, Liu Dengxiang, Zhang Lin, Li Xun, Kawada Norifumi, Jiang Zicheng, Wang Fengmei, Xiong Bin, Takehara Tetsuo, Rockey Don C
机构信息
CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China
CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
出版信息
Gut. 2021 Feb;70(2):433-436. doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20.
Abstract
摘要
相似文献
1
Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
Gut. 2021 Feb;70(2):433-436. doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20.
2
High rates of 30-day mortality in patients with cirrhosis and COVID-19.
J Hepatol. 2020 Nov;73(5):1063-1071. doi: 10.1016/j.jhep.2020.06.001. Epub 2020 Jun 9.
3
A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019.
Scand J Gastroenterol. 2021 Apr;56(4):453-457. doi: 10.1080/00365521.2021.1881814. Epub 2021 Feb 16.
4
Impact of SARS CoV-2 /COVID-19 infection on the course of advanced chronic liver disease and hepatocellular carcinoma.
Pharmacol Rep. 2022 Dec;74(6):1306-1314. doi: 10.1007/s43440-022-00434-4. Epub 2022 Nov 17.
5
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.
Gut. 2021 Mar;70(3):531-536. doi: 10.1136/gutjnl-2020-322118. Epub 2020 Jul 13.
6
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).
Hepatol Int. 2020 Sep;14(5):690-700. doi: 10.1007/s12072-020-10072-8. Epub 2020 Jul 4.
7
Impact of COVID-19 on pre-existing liver disease.
Cir Cir. 2024;92(1):131-136. doi: 10.24875/CIRU.23000409.
8
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.
9
Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea.
Clin Mol Hepatol. 2020 Oct;26(4):562-576. doi: 10.3350/cmh.2020.0126. Epub 2020 Oct 1.
10
Poor outcomes in patients with cirrhosis and Corona Virus Disease-19.
Indian J Gastroenterol. 2020 Jun;39(3):285-291. doi: 10.1007/s12664-020-01074-3. Epub 2020 Aug 15.
引用本文的文献
1
Risk factors for severe COVID-19 outcomes in the Asia-Pacific region: a literature review.
Front Public Health. 2025 Jun 9;13:1562179. doi: 10.3389/fpubh.2025.1562179. eCollection 2025.
2
Effectiveness and Safety of Remdesivir for the Treatment of COVID-19 Patients with Liver Cirrhosis: A Retrospective Cohort Study.
Life (Basel). 2025 Mar 21;15(4):512. doi: 10.3390/life15040512.
3
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.
Inflammopharmacology. 2024 Oct;32(5):2649-2680. doi: 10.1007/s10787-024-01535-7. Epub 2024 Aug 10.
4
Comparative Bioinformatic Analysis Reveals Conserved Regions in SARS-CoV-2 Genome for RAPID Pandemic Response.
Int J Mol Sci. 2024 May 25;25(11):5764. doi: 10.3390/ijms25115764.
5
Clinical characteristics of COVID-19 patients treated in emergency COVID-19 hospitals in Vietnam: Experience from Phutho province, Vietnam.
Int J Med Sci. 2024 Apr 22;21(6):1072-1078. doi: 10.7150/ijms.94461. eCollection 2024.
6
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
7
Predictors of inpatient outcomes of COVID-19 infection in patients with cirrhosis in the early pandemic phase: A nationwide survey.
JGH Open. 2023 Nov 8;7(12):889-898. doi: 10.1002/jgh3.12998. eCollection 2023 Dec.
8
Evaluation of the effects of the pandemic period on cirrhosis patients.
Prz Gastroenterol. 2023;18(3):320-326. doi: 10.5114/pg.2023.131393. Epub 2023 Sep 22.
9
Impact and management of COVID-19 in liver transplant candidates and recipients.
Ann Gastroenterol. 2023 Sep-Oct;36(5):477-489. doi: 10.20524/aog.2023.0815. Epub 2023 Jul 3.
10
COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management.
Therap Adv Gastroenterol. 2023 Jul 25;16:17562848231188586. doi: 10.1177/17562848231188586. eCollection 2023.
本文引用的文献
1
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.
Gut. 2020 Jul;69(7):1213-1217. doi: 10.1136/gutjnl-2020-321411. Epub 2020 Apr 30.
2
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
3
Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.
Clin Chim Acta. 2020 Jul;506:145-148. doi: 10.1016/j.cca.2020.03.022. Epub 2020 Mar 13.
4
COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis.
J Med Virol. 2020 Jun;92(6):577-583. doi: 10.1002/jmv.25757. Epub 2020 Mar 23.
5
Liver injury in COVID-19: management and challenges.
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4.
6
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
7
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
9
Liver Cirrhosis is Independently Associated With 90-Day Mortality in ARDS Patients.
Shock. 2016 Jan;45(1):16-21. doi: 10.1097/SHK.0000000000000487.
10
Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study.
Hepatology. 2008 Jul;48(1):214-20. doi: 10.1002/hep.22341.
Zotero 插件